



Health Economics for Personalised Medicine

HEcoPerMed

Rositsa Koleva-Kolarova, PhD
rositsa.koleva-kolarova@ndph.ox.ac.uk

 @hecopermed
<https://hecopermed.eu/>



This project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No 824997.

THE HECOPERMED PROJECT

“**Health Economics for Personalised Medicine**” (HEcoPerMed) aims to identify the **best health economic modelling** and **payment strategies** for personalised medicine in order to **recognise valuable interventions** and **stimulate their adoption** across the EU.



Erasmus School of
Health Policy
& Management



syreon
Research Institute

EcoPerMed



Doris Schartinger



Maren Walgenbach



Maureen Rutten-van
Mülken



Balázs Nagy



Sarah Wordsworth



Manuela Kienegger



Wolfgang Ballensiefen



Heleen Vellekoop



László Szilberhorn



Rositsa Koleva Kolarova



Andreas Weinhäusel



Simone Huygens



Tamás Zelei



Apostolos Tsiachristas




Günter Schreier



Matthijs Versteegh

OVERVIEW HECOPERMED PROJECT



WHAT WE ACHIEVED

Modelling guidance

Net benefit of PM

Position paper

Financing & reimbursement



...Economic

App
http

R

Fi
A

Ro
Ma
Ap

Acc



ine:
otions

hijis Versteegh².
ordsworth^{1,6}.



Position Paper: "Personalised Medicine from a Health Economic Perspective" - Lessons Learned and Potential Opportunities Ahead

Findings & Statements by the HEcoPerMed consortium

WHAT 'S NEXT

Special issue:

- Health economic modelling and budget impact analysis of:
 - Tumour agnostic treatments for NTRK gene fusion-positive (NTRK+) cancers
 - DPYD genotyping prior to fluoropyrimidine-based chemotherapy (ToxNav)
 - Maturity onset diabetes of the young
- Financial incentives to promote personalized medicine